Advisors Support J&J’s Carvykti and BMS’ Abecma for Earlier Treatment
Atlanta, Georgia – FDA advisers have given their support to J&J and Legend’s Carvykti and BMS’ Abecma for use in earlier stages of treatment, despite initial concerns regarding the potential for early patient deaths. The decision marks a significant milestone in the pharmaceutical industry, as these treatments could now be provided to patients earlier on in their disease progression, potentially improving outcomes and quality of life. Carvykti and Abecma offer new hope for patients with …